GlassScriptPhysician profile
Zwinda S Ortiz-Roldan
NPI 1609838127
$7,673.77
in general payments reported to CMS, 2019-2025
40 companies · $215 in 2025
The $215 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,489 · 2020: $839 · 2021: $1,461 · 2022: $1,490 · 2023: $1,213 · 2024: $966 · 2025: $215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,394.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,394.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,019.68 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $708.00 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $653.58 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $608.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $566.20 | 2019-2024 | Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.03 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Glaxosmithkline, LLC. | $360.45 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $322.09 | 2019-2025 | |
| Abbott Laboratories | $322.06 | 2021-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $281.63 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $236.08 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Exact Sciences Corporation | $195.25 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $184.19 | 2019-2024 | Spravato |
| Daiichi Sankyo INC. | $182.20 | 2019-2025 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $176.18 | 2022-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zwinda Ortiz-Roldan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.